Metabolic correlates of menopause: An update

Current Opinion in Obstetrics and Gynecology

Volumn 24, Issue 6, 2012, Pages 402-407

  Ross, Lauren A ^a   Polotsky, Alex J ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

menopause; metabolic syndrome; obesity

Indexed keywords

25 HYDROXYVITAMIN D; ADIPONECTIN; FERRITIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INOSITOL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MITOCHONDRIAL DNA; TESTOSTERONE; TRIACYLGLYCEROL; URIC ACID;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DISEASE PREDISPOSITION; FERRITIN BLOOD LEVEL; GENE DOSAGE; GENETIC POLYMORPHISM; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HOT FLUSH; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPODYSTROPHY; MENOPAUSE; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; MICROANGIOPATHY; NEOPLASM; NIGHT SWEAT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINOPATHY; REVIEW; SLEEP DISORDERED BREATHING; SYSTOLIC BLOOD PRESSURE; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; TRIPLE NEGATIVE BREAST CANCER; URIC ACID BLOOD LEVEL; VITAMIN BLOOD LEVEL;

BIOLOGICAL MARKERS; FEMALE; HUMANS; MENOPAUSE; METABOLIC SYNDROME X;

EID: 84870247080     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0b013e32835a91bc     Document Type: Review

References (58)

1. Polotsky HN, Polotsky AJ. Metabolic implications of menopause. Semin Reprod Med 2010; 28:426-434.
2. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37:1595-1607. (Pubitemid 19004941)
3. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome: a new worldwide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23:469-480.
4. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143-3421.
5. Nilsson PM. Cardiovascular risk in the metabolic syndrome: fact or fiction? Curr Cardiol Rep 2007; 9:479-485. (Pubitemid 350081419)
6. Leiter LA, Fitchett DH, Gilbert RE, et al. Cardiometabolic risk in Canada: a detailed analysis and position paper by the cardiometabolic risk working group. Can J Cardiol 2011; 27:e1-e33.
7. Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007; 49:403-414. (Pubitemid 46135879)
8. Wilson PW, D'agnostino RB, Parise H, et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112:3066-3072. (Pubitemid 43113437)
9. Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol 2006; 47:1093-1100.
10. Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care 2008; 31:1898-1904.
11. Meigs JB, Rutter MK, Sullivan LM, et al. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care 2007; 30:1219-1225. (Pubitemid 46684651)
12. Cornier MA, Dabelea D, Hernandez TL, et al. The metabolic syndrome. Endocr Rev 2008; 29:777-822.
13. Lee SW, Jo HH, Kim MR, et al. Association between menopausal symptoms and metabolic syndrome in postmenopausal women. Arch Gynecol Obstet 2012; 285:541-548.
14. Soules MR, Sherman S, Parrott E, et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW) Park City, Utah, July, 2001. Menopause 2001; 8:402-407. (Pubitemid 33111575)
15. Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of reproductive aging workshop\+10: addressing the unfinished agenda of staging reproductive aging. Fertil Steril 2012; 97:843-851.
16. Wing RR, Matthews KA, Kuller LH, et al. Weight gain at the time of menopause. Arch Intern Med 1991; 151:97-102.
17. Department of Health and Human Services Centers for Disease Control and Prevention. National Diabetes Fact Sheet 2011. 2011. http://www.cdc.gov/ diabetes/pubs/pdf/ndfs-2011.pdf. [Accessed 30 June 2012].
18. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 2003; 88:2404-2411. (Pubitemid 36724404)
19. Derby CA, Crawford SL, Pasternak RL, et al. Lipid changes during the menopause transition in relation to age and weight: the Study of Women's Health Across the Nation. Am J Epidemiol 2009; 169:1352-1361.
20. Coylewright M, Reckelhoff JF, Ouyang P. Menopause and hypertension: an age-old debate. Hypertension 2008; 51:952-959. (Pubitemid 351398967)
21. Janssen I, Powell LH, Crawford SL, et al. Menopause and the metabolic syndrome: the Study of Women's Health Across the Nation. Arch Intern Med 2008; 168:1568-1575.
22. Torrens JI, Sutton-Tyrrell K, Zhao X, et al. Relative androgen excess during the menopausal transition predicts incident metabolic syndrome in midlife women: study of Women's Health Across the Nation. Menopause 2009; 16:257-264.
23. Abdulnour J, Doucet E, Brochu M, et al. The effect of the menopausal transition on body composition and cardiometabolic risk factors: a Montreal-Ottawa New Emerging Team group study. Menopause 2012; 19:760-767.
24. Maiti B, Kundranda MN, Spiro TP, Daw HA. The association of metabolic syndrome with triple-negative breast cancer. Breast Cancer Res Treat 2010; 121:479-483.
25. Healy LA, Ryan AM, Carroll P, et al. Metabolic syndrome, central obesity and insulin resistance are associated with adverse pathological features in postmenopausal breast cancer. Clin Oncol (R Coll Radiol) 2010; 22:281-288.
26. Pasanisi P, Berrino F, De Petris M, et al. Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int J Cancer 2006; 119:236-238.
27. Bjorge T, Lukanova A, Jonsson H, et al. Metabolic syndrome and breast cancer in the me-can (metabolic syndrome and cancer) project. Cancer Epidemiol Biomarkers Prev 2010; 19:1737-1745.
28. Rosato V, Bosetti C, Talamini R, et al. Metabolic syndrome and the risk of breast cancer in postmenopausal women. Ann Oncol 2011; 22:2687-2692.
29. Kabat GC, Kim M, Caan BJ, et al. Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer. Int J Cancer 2009; 125:2704-2710.
30. Tuomilehto J, Zimmet P, Wolf E, et al. Plasma uric acid level and its association with diabetes mellitus and some biologic parameters in a biracial population of Fiji. Am J Epidemiol 1988; 127:321-336. (Pubitemid 18056385)
31. Iribarren C, Folson AR, Eckfeldt JH, et al. Correlates of uric acid and its association with asymptomatic carotid atherosclerosis: the ARIC Study. Atherosclerosis risk in communities. Ann Epidemiol 1996; 6:331-340. (Pubitemid 26299025)
32. Levine W, Dyer AR, Shekelle RB, et al. Serum uric acid and 11.5-year mortality of middle-aged women: findings of the Chicago Heart Association Detection Project in Industry. J Clin Epidemiol 1989; 42:257-267. (Pubitemid 19117031)
33. Lee HJ, Park HT, Cho GJ, et al. Relationship between uric acid and metabolic syndrome according to menopausal status. Gynecol Endocrinol 2011; 27:406-411.
34. Knekt P, Laaksonen M, Mattila C, et al. Serum vitamin D and subsequent occurrence of type 2 diabetes. Epidemiology 2008; 19:666-671.
35. Dobnig H, Pilz S, Scharnagl H, et al. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med 2008; 168:1340-1349. (Pubitemid 351930842)
36. Chacko SA, Song Y, Manson JE, et al. Serum 25-hydroxyvitamin D concentrations in relation to cardiometabolic risk factors and metabolic syndrome in postmenopausal women. Am J Clin Nutr 2011; 94:209-217.
37. Sun L, Franco OH, Hu FB, et al. Ferritin concentrations, metabolic syndrome, and type 2 diabetes in middle-aged and elderly chinese. J Clin Endocrinol Metab 2008; 93:4690-4696.
38. Gillum RF. Association of serum ferritin and indices of body fat distribution and obesity in Mexican American men-the Third National Health and Nutrition Examination Survey. Int J Obes Relat Metab Disord 2001; 25:639-645. (Pubitemid 32417632)
39. Williams MJ, Poulton R, Williams S. Relationship of serum ferritin with cardiovascular risk factors and inflammation in young men and women. Atherosclerosis 2002; 165:179-184. (Pubitemid 35223181)
40. Fernandez-Real JM, Ricart-Engel W, Arroyo E, et al. Serum ferritin as a component of the insulin resistance syndrome. Diabetes Care 1998; 21:62-68. (Pubitemid 28030387)
41. Piperno A, Trombini P, Gelosa M, et al. Increased serum ferritin is common in men with essential hypertension. J Hypertens 2002; 20:1513-1518. (Pubitemid 34921174)
42. Wolff B, Volzke H, Ludemann J, et al. Association between high serum ferritin levels and carotid atherosclerosis in the study of health in Pomerania (SHIP). Stroke 2004; 35:453-457. (Pubitemid 38174429)
43. Zacharski LR, Ornstein DL, Woloshin S, Schwartz LM. Association of age, sex, and race with body iron stores in adults: analysis of NHANES III data. Am Heart J 2000; 140:98-104. (Pubitemid 30471247)
44. Cho GJ, Shin JH, Yi KW, et al. Serum ferritin levels are associated with metabolic syndrome in postmenopausal women but not in premenopausal women. Menopause 2011; 18:1120-1124.
45. Ouyang P, Valdya D, Dobs A, et al. Sex hormone levels and subclinical atherosclerosis in postmenopausal women: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 2009; 204:255-261.
46. Polotsky AJ, Allshouse A, Crawford S, et al. Relative contributions of oligomenorrhea and hyperandrogenemia to the risk of metabolic syndrome in midlife women. J Clin Endocrinol Metab 2012; 97:E868-E877.
47. Org E, Eyhermendy S, Juhanson P, et al. Genome-wide scan identifies CDH13 as a novel susceptibility locus contributing to blood pressure determination in two European populations. Hum Mol Genet 2009; 18: 2288-2296.
48. Takeuchi T, Adachi Y, Ontsuki Y, Furihata M. Adiponectin receptors, with special focus on the role of the third receptor, T-cadherin, in vascular disease. Med Mol Morphol 2007; 40:115-120. (Pubitemid 47415941)
49. Fava C, Danese E, Mantagnana M, et al. A variant upstream of the CDH13 adiponectin receptor gene and metabolic syndrome in Swedes. Am J Cardiol 2011; 108:1432-1437.
50. Kim JH, Im JA, Lee DC. The relationship between leukocyte mitochondrial DNA contents and metabolic syndrome in postmenopausal women. Menopause 2012; 19:582-587.
51. Borras C, Gambini J, Lopez-Gureso R, et al. Direct antioxidant and protective effect of estradiol on isolated mitochondria. Biochim Biophys Acta 2010; 1802:205-211.
52. Lee HK, Song JH, Shin CS, et al. Decreased mitochondrial DNA content in peripheral blood precedes the development of noninsulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1998; 42:161-167. (Pubitemid 29009776)
53. Lee JE, Park H, Ju Y, et al. Higher mitochondrial DNA copy number is associated with lower prevalence of microalbuminuria. Exp Mol Med 2009; 41:253-258.
54. Lee JW, Park KD, Im JA, et al. Mitochondrial DNA copy number in peripheral blood is associated with cognitive function in apparently healthy elderly women. Clin Chim Acta 2010; 411:592-596.
55. Kim MY, Lee JW, Kang HC, et al. Leukocyte mitochondrial DNA (mtDNA) content is associated with depression in old women. Arch Gerontol Geriatr 2011; 53:e218-e221.
56. Giordano D, Corrado F, Santamaria A, et al. Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study. Menopause 2011; 18:102-104.
57. Saltiel AR. Second messengers of insulin action. Diabetes Care 1990; 13:244-256. (Pubitemid 20092111)
58. Joseph LJ, Prigeon RL, Blumenthal JB, et al. Weight loss and low-intensity exercise for the treatment of metabolic syndrome in obese postmenopausal women. J Gerontol A Biol Sci Med Sci 2011; 66:1022-1029.